Advertisement
Canada markets open in 58 minutes

  • S&P/TSX

    21,873.72
    -138.00 (-0.63%)
     

  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     

  • DOW

    38,460.92
    -42.77 (-0.11%)
     

  • CAD/USD

    0.7301
    +0.0003 (+0.04%)
     

  • CRUDE OIL

    83.29
    +0.48 (+0.58%)
     

  • Bitcoin CAD

    87,631.16
    -3,578.50 (-3.92%)
     

  • CMC Crypto 200

    1,362.96
    -19.61 (-1.42%)
     

  • GOLD FUTURES

    2,338.60
    +0.20 (+0.01%)
     

  • RUSSELL 2000

    1,995.43
    -7.22 (-0.36%)
     

  • 10-Yr Bond

    4.6520
    0.0000 (0.00%)
     

  • NASDAQ futures

    17,468.00
    -196.50 (-1.11%)
     

  • VOLATILITY

    16.36
    +0.39 (+2.44%)
     

  • FTSE

    8,103.00
    +62.62 (+0.78%)
     

  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     

  • CAD/EUR

    0.6816
    -0.0003 (-0.04%)
     
MARKETS LIVE BLOG:

STOCK FUTURES SLIDE AFTER META'S REALITY CHECK, WITH GDP ON DECK

Owner of Facebook and Instagram plans to spend up to US$10B on AI infrastructure investments

Today’s Research Reports on ESSA Pharma, Helius Medical Technologies, ProMetic Life Sciences and Resverlogix

ACCESSWIRE

NEW YORK, NY / ACCESSWIRE / February 6, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at http://rdinvesting.com and get exclusive access to our numerous research reports and market updates.

RDI has Initiated Coverage Today on:

ESSA Pharma Inc.
https://rdinvesting.com/news/?ticker=EPI.V

Helius Medical Technologies, Inc.
https://rdinvesting.com/news/?ticker=HSM.TO

ProMetic Life Sciences Inc.
https://rdinvesting.com/news/?ticker=PLI.TO

Resverlogix Corp.
https://rdinvesting.com/news/?ticker=RVX.TO

ADVERTISEMENT

ESSA Pharma's stock jumped 8.00% Monday, to close the day at $0.27. The stock recorded a trading volume of 76,656 shares, which was above its three months average volume of 73,108 shares. In the last year, ESSA Pharma's shares have traded in a range of 0.22 - 0.45. The share price has gained 22.73% from its 52 week low. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $0.27 is below its 200-day moving average of $0.31. Shares of ESSA Pharma have fallen approximately 87.97 percent year-to-date.

Access RDI's ESSA Pharma Inc. Research Report at:
https://rdinvesting.com/news/?ticker=EPI.V

On Monday, shares of Helius Medical Technologies recorded a trading volume of 12,993 shares, which was below the three months average volume of 30,680 shares. The stock ended the day 8.89% lower at 11.28. The share price has gained 466.83% from its 52 week low with a 52 week trading range of 1.99 - 25.45. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $13.97 is below its 200-day moving average of $15.48. Shares of Helius Medical Technologies have fallen approximately 29.28 percent year-to-date.

Access RDI's Helius Medical Technologies, Inc. Research Report at:
https://rdinvesting.com/news/?ticker=HSM.TO

ProMetic Life Sciences' stock moved 6.47% lower Monday, to close the day at $1.59. The stock recorded a trading volume of 1,036,383 shares, which was above its three months average volume of 885,811 shares. In the last year, ProMetic Life Sciences' shares have traded in a range of 1.12 - 2.64. The share price has gained 41.96% from its 52 week low. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $1.55 is greater than its 200-day moving average of $1.47. Shares of ProMetic Life Sciences have gained approximately 22.31 percent year-to-date.

Access RDI's ProMetic Life Sciences Inc. Research Report at:
https://rdinvesting.com/news/?ticker=PLI.TO

On Monday, shares in Resverlogix recorded a trading volume of 64,107 shares, which was below the three months average volume of 65,598 shares. The stock ended the day 1.64% lower at 1.80. The share price has gained 46.34% from its 52 week low with a 52 week trading range of 1.23 - 2.47. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $1.96 is greater than its 200-day moving average of $1.57. Shares of in Resverlogix have fallen approximately 12.2 percent year-to-date.

Access RDI's Resverlogix Corp. Research Report at:
https://rdinvesting.com/news/?ticker=RVX.TO

Our Actionable Research on ESSA Pharma Inc. (TSXV:EPI.V), Helius Medical Technologies, Inc. (TSX:HSM.TO), ProMetic Life Sciences Inc. (TSX:PLI.TO) and Resverlogix Corp. (TSX:RVX.TO) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com